Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer.

Tan G, Wang H, Yuan J, Qin W, Dong X, Wu H, Meng P.

Sci Rep. 2017 Apr 6;7:46176. doi: 10.1038/srep46176.

2.

Solute carrier family 12 member 5 promotes tumor invasion/metastasis of bladder urothelial carcinoma by enhancing NF-κB/MMP-7 signaling pathway.

Liu JY, Dai YB, Li X, Cao K, Xie D, Tong ZT, Long Z, Xiao H, Chen MK, Ye YL, Liu B, Tan J, Tang J, Xu ZZ, Gan Y, Zhou YH, Deng F, He LY.

Cell Death Dis. 2017 Mar 23;8(3):e2691. doi: 10.1038/cddis.2017.118.

3.

Can lymphovascular invasion replace the prognostic value of lymph node involvement in patients with upper tract urothelial carcinoma after radical nephroureterectomy?

Yoo ES, Ha YS, Lee JN, Kim BS, Kim BW, Byun SS, Choi YD, Kang HW, Yun SJ, Kim WJ, Kim JH, Kwon TG.

Can Urol Assoc J. 2016 Jul-Aug;10(7-8):E229-E236. doi: 10.5489/cuaj.3557. Epub 2016 Jul 12.

4.

Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder Cancer.

Olkhov-Mitsel E, Savio AJ, Kron KJ, Pethe VV, Hermanns T, Fleshner NE, van Rhijn BW, van der Kwast TH, Zlotta AR, Bapat B.

Transl Oncol. 2017 Apr;10(2):168-177. doi: 10.1016/j.tranon.2017.01.001. Epub 2017 Feb 3.

5.

Impact of the ASA Physical Status Score on Adjuvant Chemotherapy Eligibility and Survival of Upper Tract Urothelial Carcinoma Patients: a Multicenter Study.

Kang HW, Seo SP, Kim WT, Kim YJ, Yun SJ, Lee SC, Choi YD, Ha YS, Kim TH, Kwon TG, Byun SS, Jeh SU, Kim WJ.

J Korean Med Sci. 2017 Feb;32(2):335-342. doi: 10.3346/jkms.2017.32.2.335.

6.

Carbonic anhydrase 2 is a novel invasion-associated factor in urinary bladder cancers.

Tachibana H, Gi M, Kato M, Yamano S, Fujioka M, Kakehashi A, Hirayama Y, Koyama Y, Tamada S, Nakatani T, Wanibuchi H.

Cancer Sci. 2017 Mar;108(3):331-337. doi: 10.1111/cas.13143.

7.

Expression profile of SPACA5/Spaca5 in spermatogenesis and transitional cell carcinoma of the bladder.

Zhang XY, Yan QX, Guo XY, Chen CR, Chen RQ, Cai ZM, Tang AF.

Oncol Lett. 2016 Nov;12(5):3731-3738. Epub 2016 Sep 21.

8.

Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.

Critelli R, Fasanelli F, Oderda M, Polidoro S, Assumma MB, Viberti C, Preto M, Gontero P, Cucchiarale G, Lurkin I, Zwarthoff EC, Vineis P, Sacerdote C, Matullo G, Naccarati A.

Oncotarget. 2016 Oct 11;7(41):67435-67448. doi: 10.18632/oncotarget.11883.

9.

Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20, CD44, P53 and Ki67.

Asgari M, Nabi Maybodi M, Abolhasani M.

Med J Islam Repub Iran. 2016 Jul 18;30:400. eCollection 2016.

10.

Clinical Behavior of Bladder Urothelial Carcinoma in Young Patients: A Single Center Experience.

Sen V, Bozkurt O, Demir O, Esen AA, Mungan U, Aslan G, Kefi A, Celebi I.

Scientifica (Cairo). 2016;2016:6792484. doi: 10.1155/2016/6792484. Epub 2016 Aug 2.

11.

Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier.

Garcia PV, Seiva FR, Carniato AP, de Mello Júnior W, Duran N, Macedo AM, de Oliveira AG, Romih R, Nunes Ida S, Nunes Oda S, Fávaro WJ.

BMC Cancer. 2016 Jul 7;16:422. doi: 10.1186/s12885-016-2474-z.

12.

Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.

Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ.

Bladder Cancer. 2016 Apr 27;2(2):165-202.

13.

Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study.

Passoni NM, Shariat SF, Bagrodia A, Francis F, Rachakonda V, Xylinas E, Kapur P, Sagalowsky AI, Lotan Y.

Bladder Cancer. 2016 Jan 7;2(1):91-99.

14.

Nuclear size measurement for distinguishing urothelial carcinomas from reactive urothelium on tissue sections.

Poropatich K, Yang JC, Goyal R, Parini V, Yang XJ.

Diagn Pathol. 2016 Jun 30;11(1):57. doi: 10.1186/s13000-016-0501-7.

15.

Radical cystectomy with pelvic lymphadenectomy: pathologic, operative and morbidity outcomes in a Brazilian cohort.

Corradi RB, Galvao GJ, Oliveira GM, Carneiro VF, Miconi WG, Salles PG, Cabral WL, Corradi C, Salazar AL.

Int Braz J Urol. 2016 May-Jun;42(3):431-7. doi: 10.1590/S1677-5538.IBJU.2015.0380.

16.

The pathology of urinary bladder lesions with an inverted growth pattern.

Guo A, Liu A, Teng X.

Chin J Cancer Res. 2016 Feb;28(1):107-21. doi: 10.3978/j.issn.1000-9604.2016.02.01. Review.

17.

Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer.

Kim YH, Yan C, Lee IS, Piao XM, Byun YJ, Jeong P, Kim WT, Yun SJ, Kim WJ.

Investig Clin Urol. 2016 Mar;57(2):106-12. doi: 10.4111/icu.2016.57.2.106. Epub 2016 Mar 11.

18.

Preliminary Analysis of the Expression of Selected Proangiogenic and Antioxidant Genes and MicroRNAs in Patients with Non-Muscle-Invasive Bladder Cancer.

Kozakowska M, Dobrowolska-Glazar B, Okoń K, Józkowicz A, Dobrowolski Z, Dulak J.

J Clin Med. 2016 Feb 25;5(3). pii: E29. doi: 10.3390/jcm5030029.

19.

Immediate Radical Cystectomy for Massive Bleeding of Bladder Cancer.

Cochetti G, Barillaro F, Boni A, Mearini E.

Biomed Res Int. 2015;2015:154392. doi: 10.1155/2015/154392. Epub 2015 Dec 24.

20.

A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance.

Sapre N, Macintyre G, Clarkson M, Naeem H, Cmero M, Kowalczyk A, Anderson PD, Costello AJ, Corcoran NM, Hovens CM.

Br J Cancer. 2016 Feb 16;114(4):454-62. doi: 10.1038/bjc.2015.472. Epub 2016 Jan 26.

Supplemental Content

Support Center